Influence of interleukin-13 on beta-catenin levels in eosinophilic chronic rhinosinusitis cell culture.
Chronic rhinosinusitis (CRS) is one of the most common chronic diseases. The etiology and classification of CRS, with and without nasal polyps, remain unclear. Eosinophils and their products are important in the pathophysiology of allergic diseases and in host immunity to certain organisms. Interleukin 13 (IL-13) plays a pivotal role in eosinophilic inflammation. The migration of epithelial cells requires permanent re-establishment of the intercellular connection. Intercellular connections are maintained by the modulation of adherens junctions consisting of an E-cadherin/beta-catenin complex. In our study we examined the eosinophilic and non-eosinophilic paranasal mucosa obtained from two patients undergoing functional endoscopic sinus surgery. Cell cultures were incubated with human recombinant IL-13 for up to 72 h and beta-catenin concentration was determined with ELISA techniques. Furthermore, immunostaining for beta-catenin was used for the semi-quantitative description of specimens. We were able to ascertain a significant increase in beta-catenin expression in the eosinophilic paranasal cell culture after IL-13 administration compared to the non-eosinophilic culture. Immunostaining for beta-catenin was restricted to the membrane of the cells. Concerning the increased mural expression of beta-catenin, we presume that a fibrotic reaction similar to asthma and chronic obstructive pulmonary disease occurs in patients suffering from CRS. Furthermore, beta-catenin overexpression might be responsible for mucosal thickening and IL-13 seems to be an important marker in eosinophilic CRS.
Sauter
Alexander
A
Universitäts-HNO-Klinik, Theodor-Kutzer-Ufer, D-68135 Mannheim, Germany. alexander.sauter@googlemail.com
Stern-Straeter
Jens
J
Chang
Ray C
RC
Hörmann
Karl
K
Naim
Ramin
R
D002478:Cells, Cultured; D002908:Chronic Disease; D004802:Eosinophilia / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D018793:Interleukin-13 / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D020545:Respiratory Mucosa / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D012220:Rhinitis / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D012852:Sinusitis / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D051176:beta Catenin / Q000378:metabolism*
C495270:CTNNB1 protein, human; D018793:Interleukin-13; D011994:Recombinant Proteins; D051176:beta Catenin